MINERALYS THERAPEUTICS, INC. Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent
MINERALYS THERAPEUTICS, INC. (MLYS) had Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent of $0 as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Long-Term Investments
us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLossNoncurrent · last filed 2025-02-12
- 2024-09-30: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent $0.00.
- 2024-06-30: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent $0.00.
- 2024-03-31: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent $0.00.
- 2023-12-31: Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent $2.48M.
| Period end | Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent |
|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.48M 10-K · filed 2025-02-12 |
| 2023-09-30 | $12.13M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $21.68M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $31.12M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |